Health, Longevity & Biohacking
GLP-1 Drug Stabilizes Parkinson's Disease in First-Ever Disease-Modifying Treatment Study
Feel Better, Live More with Dr Rangan Chatterjee
Brain Doctor: The Foods Quietly Raising Your Alzheimer's Risk (It's NOT Sugar) | David Perlmutter
"In 2024 a fascinating study and I talk about it in the book was published in the New England Journal of Medicine. 135 Parkinson's patients were randomized to receive a GLP-1 ompic like drug or placebo for one year and the results were dramatic. The group receiving the placebo continued to decline as we would see in Parkinson's, but the group receiving the GLP-1 drug stabilized slightly improves on what is called the unified Parkinson's disease rating scale."
A 2024 New England Journal of Medicine study showed that a GLP-1 drug (similar to Ozempic) stabilized and slightly improved Parkinson's patients over one year, marking the first time a treatment addressed the underlying metabolic dysfunction rather than just symptoms. Perlmutter suggests this breakthrough validates the mitochondrial dysfunction theory underlying neurodegenerative diseases. The drug is not currently available in America due to pancreatic concerns, but opens new therapeutic pathways.
From this episode
Feel Better, Live More with Dr Rangan Chatterjee